John Libbey Eurotext

European Journal of Dermatology


Lichenoid drug eruption caused by adalimumab: a case report and literature review Volume 27, issue 1, January-February 2017


  • Figure 1
Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

Monoclonal antibodies against tumour necrosis factor (TNF) α are widely used for the treatment of autoimmune diseases, such as rheumatoid arthritis (RA). Adalimumab is one of the recombinant human TNF-α receptor antibodies used for the treatment of severe RA. Several cutaneous adverse events due to adalimumab have been reported. Herein, we report a patient with a lichenoid drug eruption caused by adalimumab. We also review cases of lichenoid drug eruptions caused by biological drugs. Since cytokine [...]